Oppenheimer weighs in on Capricor Therapeutics (CAPR) following FDA letter and CEO meeting
Tweet Send to a Friend
Oppenheimer analyst Leland Gershall reiterated an Outperform rating and $43.00 price target on Capricor Therapeutics (NASDAQ: CAPR) following the FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
